COVID-19 and neuromuscular disorders
COVID-19 and neuromuscular disorders
复制标题
DOI：
10.1212/wnl.0000000000009566
复制
发表时间：
2020-06-02
期刊：
影响因子：
9.9
通讯作者：
Amato, Anthony A.
中科院分区：
文献类型：
--
作者：
Guidon, Amanda C.;Amato, Anthony A.
2019 年冠状病毒 (COVID-19) 大流行有可能对神经肌肉疾病患者造成不成比例的严重影响。在短时间内，它已经引起了神经肌肉临床护理服务和教育的重组，这可能会对该领域产生持久影响。本文综述了 (1) COVID-19 的潜在神经肌肉并发症，(2) 对既存神经肌肉疾病患者的 COVID-19 相关风险评估和缓解，(3) 免疫抑制和免疫调节治疗管理指南，(4) 有关神经肌肉护理、远程医疗和教育的实用指南，以及 (5) 对神经肌肉研究的影响。我们概述了尚未解答的关键临床问题，并强调了基于团队和跨专业合作的必要性。在此期间临床研究的主要目标是开发基于证据的最佳实践，并尽量减少神经肌肉疾病患者与 COVID-19 相关的发病率和死亡率。
The coronavirus 2019 (COVID-19) pandemic has potential to disproportionately and severely affect patients with neuromuscular disorders. In a short period of time, it has already caused reorganization of neuromuscular clinical care delivery and education, which will likely have lasting effects on the field. This article reviews (1) potential neuromuscular complications of COVID-19, (2) assessment and mitigation of COVID-19-related risk for patients with preexisting neuromuscular disease, (3) guidance for management of immunosuppressive and immunomodulatory therapies, (4) practical guidance regarding neuromuscular care delivery, telemedicine, and education, and (5) effect on neuromuscular research. We outline key unanswered clinical questions and highlight the need for team-based and interspecialty collaboration. Primary goals of clinical research during this time are to develop evidence-based best practices and to minimize morbidity and mortality related to COVID-19 for patients with neuromuscular disorders.